MedX Health’s global sales team discuss the commercialization of their teledermatology screening platform across North America, Europe and the Middle East
In a recent InvestorIntel interview, Tracy Weslosky spoke with Mike Druhan, President of Dermatology Services, Naman Demaghlatrous, Managing Director, Europe, Middle East & Africa and Dr. Paul Ziemer, Managing Director, North America at MedX Health Corp. (TSXV: MDX) about how MedX Health’s global sales team is driving commercialization of their teledermatology screening platform across North America, Europe and the Middle East.
In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Mike Druhan said that MedX’s teledermatology platform is built on DermSecure™, which provides detailed patient scans for virtual dermatological assessment by a certified dermatologist within just 72 hours. As the healthcare system moves towards improving patients’ accessibility to healthcare, Naman Demaghlatrous explained how MedX Health can provide access to the best dermatology specialists even in remote areas and help save lives.
To watch the full interview, click here
About MedX Health Corp.
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on the DermSecure® telemedicine platform, which utilizes its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its reflectance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images within seconds for physicians and dermatologists to evaluate all types of moles or lesions. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey.
To learn more about MedX Health Corp., click here
Disclaimer: MedX Health Corp. is an advertorial member of InvestorIntel Corp.
This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.
This presentation may contain“forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.
Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.
If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at email@example.com.